Latest news for Recordati (OTC:RCDTF) Stock

Recordati SpA is a drug manufacturing company that focuses on specialty pharmaceuticals. The company produces and promotes medicines globally that focus on primary-care therapies and rare diseases. Recordati uses strategic partnerships as part of its long-term growth. The vast majority of the company's revenue is generated in Italy, followed by the United States, France, and Germany. Recordati reports two operating segments: Specialty and Primary care and Rare diseases. The bulk of the company's profit is derived from its specialty and primary care segment which includes the production of active ingredients.

RECORDATI INDUSTRIA CHIM by Recordati Industria Chimica e Farmaceutica S.p.A.

Recordati SpA

Recordati

Recordati (OTC: <a class="ticker" href="/stock/rcdtf#OTC">RCDTF</a>) announces that the U.S. Food and Drug Administration has granted approval of Orphan Europe's request for orphan drug designation for the use of Carbaglu® (carglumic acid) in the treatment of organic acidemias (OAs).

	The term organic acidemias (OAs) applies to a group of serious life-threatening disorders characterized by excretion of non-amino organic acids in urine. Most organic acidemias (OAs) result from dysfunction of a specific step in amino acid catabolism usually the result of deficient enzyme activity. Classic organic acidemias (OAs) such as isovaleric acidemia (IVA), propionic acidemia (PA) and methylmalonic acidemia (MMA) are autosomal recessive disorders of branched-chain amino acid metabolism (leucine, isoleucine, valine).

	Orphan drug designation applies to drugs that seek to treat rare diseases or conditions affecting fewer than 200,000 patients in the U.S. while providing significant therapeutic advantage over existing therapies. The designation provides the opportunity for seven years marketing exclusivity upon approval for the designated indication, tax credits to offset clinical research expenses, the ability to apply for annual grant funding, and the potential waiver of prescription drug user fees.

	Carbaglu® is currently marketed in the U.S. by Recordati Rare Diseases for pediatric and adult patients as the
    
    <a href="http://www.benzinga.com/pressreleases/14/07/g4679652/recordati-carbaglu-r-receives-orphan-drug-designation-in-the-u-s-for-or">See full press release</a>

Comments

Recordati

News

Latest news for Recordati (OTC:RCDTF) Stock

Thursday, July 03, 2014

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga